Published in Physician Law Weekly, May 13th, 2009
Net product sales of ENTEREG® (alvimopan) recognized for the three months ended March 31, 2009 were approximately $1.4 million on total net shipments of approximately $2.0 million. Under Adolor's current revenue recognition policy, revenue related to a customer shipment is deferred until subsequent re-orders by that customer. Since the Company's launch of ENTEREG in June 2008, approximately 300 hospitals have re-ordered the product.
Hospitals registered under the ENTEREG Access Support and Education (E.A.S.E.™) Program increased by 175 to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly